DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
Imara’s investigational oral inhibitor IMR-687 is well-tolerated, and shows signs of potential for lowering blood biomarkers of sickle cell anemia (SCA), early data from a Phase 2 trial show. The results were presented at the 24th Congress of the European Hematology Association (EHA), held recently in Amsterdam, the Netherlands.
“We are encouraged by this interim Phase 2a analysis that reinforces our belief in the potential of IMR-687 as a single oral, once-a-day therapeutic,” Rahul D. Ballal, CEO of Imara, said in a press release.
“IMR-687 uniquely targets both red cell and white cell aspects of the disease, and we are working to expeditiously advance this novel therapy through clinical development, with a goal of delivering it to patients with SCD [sickle cell disease] who are in need of innovative treatment options,” Ballal added.
The highly potent therapy is an oral inhibitor of the phosphodiesterase 9 (PDE9) enzyme found in red blood cells. Inhibition of PDE9 in preclinical studies with cells and animal models showed that IMR-687 increases fetal hemoglobin.
education & researchPrevention of acute sickle cell crisis: review of the NEJM reportA recent article in the New England Jour...
videos & visualsFOA TA Webinar: Sickle Cell Disease Clinical Data Collection Platformhttps://www.youtube.com/watch?v=8afutDfe...
news & eventsFirst Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
news & eventsCalifornia Institute For Regenerative Medicine Awards City Of Hope $5.74 Million For Severe Sickle Cell Disease Clin...The California Institute for Regenerativ...
news & eventsGBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
education & researchA Phase 3 Randomized Trial of Voxelotor in Sickle Cell DiseaseBackground: Deoxygenated sickle hemog...
news & eventsGlobal Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
send a message
Don’t forget to join the oneSCDvoice community!
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.